Enzalutamide monotherapy in hormone-naive prostate cancer: Primary analysis of an open-label, single-arm, phase 2 study

The Lancet Oncology

Volumn 15, Issue 6, 2014, Pages 592-600

  Tombal, Bertrand ^a   Borre, Michael ^b   Rathenborg, Per ^c   Werbrouck, Patrick ^d   Van Poppel, Hendrik ^e   Heidenreich, Axel ^f   Iversen, Peter ^g   Braeckman, Johan ^h   Heracek, Jiri ⁱ   Baskin Bey, Edwina ^j   Ouatas, Taoufik ^j   Perabo, Frank ^k   Phung, De ^j   Hirmand, Mohammad ^l   Smith, Matthew R ^m  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AZ GROENINGE   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f RWTH AACHEN UNIVERSITY   (Germany)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j Astellas Pharma Global Development   (Netherlands)

^k ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^l Medivation Inc   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BLADDER CARCINOMA; BLOOD LEVEL; CALCIFICATION; CANCER FATIGUE; CANCER SCREENING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FAINTNESS; FOLLOW UP; GYNECOMASTIA; HEART ARREST; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE DISEASE; RASH; RHINOPHARYNGITIS; SEIZURE; TRANSITIONAL CELL CARCINOMA; UROSEPSIS; VERY ELDERLY; XEROSTOMIA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84899969509     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70129-9     Document Type: Article

References (32)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer 2013, European Association of Urology, Arnhem, (accessed March 13, 2014). http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf.
2. DiBlasio CJ, Malcolm JB, Derweesh IH, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 2008, 102:39-43.
3. Taylor LG, Canfield SE, Du XL Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009, 115:2388-2399.
4. Jespersen CG, Nørgaard M, Borre M Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014, 65:704-709.
5. Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994, 41:525-530.
6. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6·3 years of followup. J Urol 2000, 164:1579-1582.
7. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998, 33:447-456.
8. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9·7 years. BJU Int 2010, 105:1074-1081.
9. Beer TM, Armstrong A, Sternberg CN, et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer: results of phase 3 PREVAIL study. American Society of Clinical Oncology 2014 Genitourinary Cancers Symposium; San Francisco, CA, USA; Jan 30-Feb 1, 2014 http://meetinglibrary.asco.org/content/123836-142.
10. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
11. Belikov S, Oberg C, Jaaskelainen T, Rahkama V, Palvimo JJ, Wrange O FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide). Mol Cell Endocrinol 2013, 365:95-107.
12. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
14. van Andel G, Bottomley A, Fosså SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008, 44:2418-2424.
15. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 2010, US Department of Health and Human Services, National Institutes of Health, Bethesda, MA, (accessed Jan 9, 2014). http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
16. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008, 102:1531-1538.
17. Harris WP, Mostaghel EA, Nelson PS, Montgomery B Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009, 6:76-85.
18. Semenas J, Dizeyi N, Persson JL Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther 2013, 7:875-881.
19. Saylor PJ, Keating NL, Smith MR Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 2009, 24(suppl 2):S389-S394.
20. Collins L, Basaria S Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications. Asian J Androl 2012, 14:222-225.
21. Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009, 55:62-75.
22. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999, 81:242-251.
23. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
24. Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003, 62:319-323.
25. Tyrrell CJ, Iversen P, Tammela T, et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006, 98:563-572.
26. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004, 22:2546-2553.
27. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86:4261-4267.
28. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599-603.
29. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005, 90:6410-6417.
30. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83:2266-2274.
31. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
32. Soloway MS, Schellhammer PF, Smith JA, et al. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. J Urol 1995, 154:2110-2114.